康泰医学(300869) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit loss for 2024, estimated between -55 million to -105 million CNY, compared to a profit of 165.76 million CNY in the previous year[9]. - The net profit after deducting non-recurring gains and losses is projected to be between -74 million to -125 million CNY, down from a profit of 149.75 million CNY in the previous year[9]. - The decline in performance is attributed to reduced market demand, intensified industry competition, and a decrease in orders, which has narrowed profit margins[10]. - The company has recognized impairment losses on inventory, leading to a provision for inventory write-downs that negatively impacts net profit[10]. Investor Advisory - Investors are advised to pay attention to the significant expected losses for 2024 and the potential impact on the company's debt repayment capacity[12]. - The report serves as a temporary trustee management report and does not constitute any investment advice[6]. Communication and Oversight - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies between the two parties[9]. - The company will continue to monitor the situation closely and fulfill its responsibilities as a bond trustee to protect the interests of bondholders[12]. - The performance forecast is based on preliminary estimates and is subject to final audit results[9]. Report Issuance - The report was issued by CITIC Securities as the trustee for the convertible bonds issued by the company[8].